Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?

Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?

Introduction: Tildrakizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown promise in the management of moderate-to-severe plaque psoriasis, offering potential improvements in clinical outcomes and quality of life. Objectives: The study aimed to id...

Full description

Bibliographic Details
Main Authors: Eugenia Veronica Di Brizzi, Stefano Caccavale, Roberta Di Caprio, Francesco Cusano, Rocco De Pasquale, Valeria Falcomatà, Caterina Foti, Claudia Giofrè, Emanuela Gubinelli, Giampiero Mazzocchetti, Massimiliano Nicolini, Giovanni Palazzo, Leonardo Pescitelli, Rosa Valentina Puca, Oriele Sarno, Anna Balato
Format: Article
Language:English
Published: Mattioli1885 2024-10-01
Series:Dermatology Practical & Conceptual
Subjects:
tildrakizumab 200 mg
psoriasis
Anti-IL-23
psoriasis treatment
obesity
dose escalation
Online Access:http://www.dpcj.org/index.php/dpc/article/view/4769

Internet

http://www.dpcj.org/index.php/dpc/article/view/4769

Similar Items